Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: A pediatric oncology group study

Carolyn R. Freeman, Jeffrey P. Krischer, R. Alex Sanford, Michael E. Cohen, Peter C. Burger, Raquel del Carpio, Edward C. Halperin, Louis Munoz, Henry S. Friedman, Larry E. Kun

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: In September 1984, the Pediatric Oncology Group began accrual to a Phase I/II study designed to assess the efficacy and toxicity of sequentially escalated doses of hyperfractionated (twice daily) radiotherapy in children wit-h poor-prognosis brain stem tumors. Pediatric Oncology Group Study #849closed in June 1990 with a total of 136 patients on study. We report here the outcome of patients treated atthe third and final dose level (75.6 Gy), and compare the results to those obtained at the 66 and 70.2 Gy dose levels. Methods and Materials: Patients eligible for study were those between 3 and 21 years of age with previously untreated tumors arising in the midbrain, pons or medulla. Histological confirmation of diagnosis was not mandatory provided that the clinical and radiological findings were typical for brain stem glioma. Treatment consisted of radiotherapy delivered to local fields. At the third dose level, fraction sizes of 1.26 Gy were given twice dally, with a minimum interfraction interval of 6 hr to a dose of 75.6 Gy in 60 fractions over 6 weeks. Between 5 89 and 6 90, 41 patients were accrued to the study. Two were excluded from analysis leaving 39 evaluable patients, 21 male and 19 female, whose ages ranged from 3 to 15 years (median 7.5 years). Results: Following treatment, neurological improvement was reported in 30/39 (77%) of the patients. On central review of imaging studies in 29 patients, one patient was found to have had a complete response to radiotherapy, five a partial (> 50% response), and only three had non-responding or progressive disease. The median time to disease progression was 7 months; median survival time was 10 months; survival at 1 year was 39.9% (SE 8.3%) and at 2 years, 7% (SE 4.8%). The pattern of failure was local in all patients; in addition six had evidence of leptomeningeal seeding. Morbidity of treatment included an enhanced skin reaction (21%), otitis media and/or externa (26%) and steroid use > 3 months (62%). Intralesional necrosis was a frequent finding (45%) on imaging studies performed at a median time of 6 weeks post treatment. Conclusion: The results of treatment in terms of progression-free survival and overall survival are not significantly different (at p = .55 and p = .46, respectively) from those obtained at the two previous dose levels. There is no evidence that higher doses of hyperfractionated radiotherapy given as in this study improve the outlook of patients with poor-risk brain stem gliomas.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume27
Issue number2
DOIs
StatePublished - Sep 30 1993

Fingerprint

brain stem
Brain Stem Neoplasms
radiation therapy
Radiotherapy
tumors
Pediatrics
dosage
Glioma
progressions
Brain Stem
Survival
Otitis Externa
Therapeutics
Wit and Humor
steroids
Pons
prognosis
necrosis
Otitis Media
inoculation

Keywords

  • Brain stem tumors
  • Hyperfractionated radiotherapy
  • Radiotherapy
  • Treatment

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children : A pediatric oncology group study. / Freeman, Carolyn R.; Krischer, Jeffrey P.; Sanford, R. Alex; Cohen, Michael E.; Burger, Peter C.; del Carpio, Raquel; Halperin, Edward C.; Munoz, Louis; Friedman, Henry S.; Kun, Larry E.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 27, No. 2, 30.09.1993, p. 197-206.

Research output: Contribution to journalArticle

Freeman, Carolyn R. ; Krischer, Jeffrey P. ; Sanford, R. Alex ; Cohen, Michael E. ; Burger, Peter C. ; del Carpio, Raquel ; Halperin, Edward C. ; Munoz, Louis ; Friedman, Henry S. ; Kun, Larry E. / Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children : A pediatric oncology group study. In: International Journal of Radiation Oncology, Biology, Physics. 1993 ; Vol. 27, No. 2. pp. 197-206.
@article{59c4c312e3284b0db88bce02daf08c4a,
title = "Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: A pediatric oncology group study",
abstract = "Purpose: In September 1984, the Pediatric Oncology Group began accrual to a Phase I/II study designed to assess the efficacy and toxicity of sequentially escalated doses of hyperfractionated (twice daily) radiotherapy in children wit-h poor-prognosis brain stem tumors. Pediatric Oncology Group Study #849closed in June 1990 with a total of 136 patients on study. We report here the outcome of patients treated atthe third and final dose level (75.6 Gy), and compare the results to those obtained at the 66 and 70.2 Gy dose levels. Methods and Materials: Patients eligible for study were those between 3 and 21 years of age with previously untreated tumors arising in the midbrain, pons or medulla. Histological confirmation of diagnosis was not mandatory provided that the clinical and radiological findings were typical for brain stem glioma. Treatment consisted of radiotherapy delivered to local fields. At the third dose level, fraction sizes of 1.26 Gy were given twice dally, with a minimum interfraction interval of 6 hr to a dose of 75.6 Gy in 60 fractions over 6 weeks. Between 5 89 and 6 90, 41 patients were accrued to the study. Two were excluded from analysis leaving 39 evaluable patients, 21 male and 19 female, whose ages ranged from 3 to 15 years (median 7.5 years). Results: Following treatment, neurological improvement was reported in 30/39 (77{\%}) of the patients. On central review of imaging studies in 29 patients, one patient was found to have had a complete response to radiotherapy, five a partial (> 50{\%} response), and only three had non-responding or progressive disease. The median time to disease progression was 7 months; median survival time was 10 months; survival at 1 year was 39.9{\%} (SE 8.3{\%}) and at 2 years, 7{\%} (SE 4.8{\%}). The pattern of failure was local in all patients; in addition six had evidence of leptomeningeal seeding. Morbidity of treatment included an enhanced skin reaction (21{\%}), otitis media and/or externa (26{\%}) and steroid use > 3 months (62{\%}). Intralesional necrosis was a frequent finding (45{\%}) on imaging studies performed at a median time of 6 weeks post treatment. Conclusion: The results of treatment in terms of progression-free survival and overall survival are not significantly different (at p = .55 and p = .46, respectively) from those obtained at the two previous dose levels. There is no evidence that higher doses of hyperfractionated radiotherapy given as in this study improve the outlook of patients with poor-risk brain stem gliomas.",
keywords = "Brain stem tumors, Hyperfractionated radiotherapy, Radiotherapy, Treatment",
author = "Freeman, {Carolyn R.} and Krischer, {Jeffrey P.} and Sanford, {R. Alex} and Cohen, {Michael E.} and Burger, {Peter C.} and {del Carpio}, Raquel and Halperin, {Edward C.} and Louis Munoz and Friedman, {Henry S.} and Kun, {Larry E.}",
year = "1993",
month = "9",
day = "30",
doi = "10.1016/0360-3016(93)90228-N",
language = "English (US)",
volume = "27",
pages = "197--206",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children

T2 - A pediatric oncology group study

AU - Freeman, Carolyn R.

AU - Krischer, Jeffrey P.

AU - Sanford, R. Alex

AU - Cohen, Michael E.

AU - Burger, Peter C.

AU - del Carpio, Raquel

AU - Halperin, Edward C.

AU - Munoz, Louis

AU - Friedman, Henry S.

AU - Kun, Larry E.

PY - 1993/9/30

Y1 - 1993/9/30

N2 - Purpose: In September 1984, the Pediatric Oncology Group began accrual to a Phase I/II study designed to assess the efficacy and toxicity of sequentially escalated doses of hyperfractionated (twice daily) radiotherapy in children wit-h poor-prognosis brain stem tumors. Pediatric Oncology Group Study #849closed in June 1990 with a total of 136 patients on study. We report here the outcome of patients treated atthe third and final dose level (75.6 Gy), and compare the results to those obtained at the 66 and 70.2 Gy dose levels. Methods and Materials: Patients eligible for study were those between 3 and 21 years of age with previously untreated tumors arising in the midbrain, pons or medulla. Histological confirmation of diagnosis was not mandatory provided that the clinical and radiological findings were typical for brain stem glioma. Treatment consisted of radiotherapy delivered to local fields. At the third dose level, fraction sizes of 1.26 Gy were given twice dally, with a minimum interfraction interval of 6 hr to a dose of 75.6 Gy in 60 fractions over 6 weeks. Between 5 89 and 6 90, 41 patients were accrued to the study. Two were excluded from analysis leaving 39 evaluable patients, 21 male and 19 female, whose ages ranged from 3 to 15 years (median 7.5 years). Results: Following treatment, neurological improvement was reported in 30/39 (77%) of the patients. On central review of imaging studies in 29 patients, one patient was found to have had a complete response to radiotherapy, five a partial (> 50% response), and only three had non-responding or progressive disease. The median time to disease progression was 7 months; median survival time was 10 months; survival at 1 year was 39.9% (SE 8.3%) and at 2 years, 7% (SE 4.8%). The pattern of failure was local in all patients; in addition six had evidence of leptomeningeal seeding. Morbidity of treatment included an enhanced skin reaction (21%), otitis media and/or externa (26%) and steroid use > 3 months (62%). Intralesional necrosis was a frequent finding (45%) on imaging studies performed at a median time of 6 weeks post treatment. Conclusion: The results of treatment in terms of progression-free survival and overall survival are not significantly different (at p = .55 and p = .46, respectively) from those obtained at the two previous dose levels. There is no evidence that higher doses of hyperfractionated radiotherapy given as in this study improve the outlook of patients with poor-risk brain stem gliomas.

AB - Purpose: In September 1984, the Pediatric Oncology Group began accrual to a Phase I/II study designed to assess the efficacy and toxicity of sequentially escalated doses of hyperfractionated (twice daily) radiotherapy in children wit-h poor-prognosis brain stem tumors. Pediatric Oncology Group Study #849closed in June 1990 with a total of 136 patients on study. We report here the outcome of patients treated atthe third and final dose level (75.6 Gy), and compare the results to those obtained at the 66 and 70.2 Gy dose levels. Methods and Materials: Patients eligible for study were those between 3 and 21 years of age with previously untreated tumors arising in the midbrain, pons or medulla. Histological confirmation of diagnosis was not mandatory provided that the clinical and radiological findings were typical for brain stem glioma. Treatment consisted of radiotherapy delivered to local fields. At the third dose level, fraction sizes of 1.26 Gy were given twice dally, with a minimum interfraction interval of 6 hr to a dose of 75.6 Gy in 60 fractions over 6 weeks. Between 5 89 and 6 90, 41 patients were accrued to the study. Two were excluded from analysis leaving 39 evaluable patients, 21 male and 19 female, whose ages ranged from 3 to 15 years (median 7.5 years). Results: Following treatment, neurological improvement was reported in 30/39 (77%) of the patients. On central review of imaging studies in 29 patients, one patient was found to have had a complete response to radiotherapy, five a partial (> 50% response), and only three had non-responding or progressive disease. The median time to disease progression was 7 months; median survival time was 10 months; survival at 1 year was 39.9% (SE 8.3%) and at 2 years, 7% (SE 4.8%). The pattern of failure was local in all patients; in addition six had evidence of leptomeningeal seeding. Morbidity of treatment included an enhanced skin reaction (21%), otitis media and/or externa (26%) and steroid use > 3 months (62%). Intralesional necrosis was a frequent finding (45%) on imaging studies performed at a median time of 6 weeks post treatment. Conclusion: The results of treatment in terms of progression-free survival and overall survival are not significantly different (at p = .55 and p = .46, respectively) from those obtained at the two previous dose levels. There is no evidence that higher doses of hyperfractionated radiotherapy given as in this study improve the outlook of patients with poor-risk brain stem gliomas.

KW - Brain stem tumors

KW - Hyperfractionated radiotherapy

KW - Radiotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0027482257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027482257&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(93)90228-N

DO - 10.1016/0360-3016(93)90228-N

M3 - Article

C2 - 8407392

AN - SCOPUS:0027482257

VL - 27

SP - 197

EP - 206

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -